Summary
Dinesh Thakur exposed data manipulation and quality issues at Ranbaxy Laboratories, leading to a US$500 million settlement and increased scrutiny of generic drug manufacturing. His actions, despite costing his corporate career, significantly impacted medicine safety and advocated for regulatory reform.